Ginkgo Bioworks Holdings, Inc. vs. Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. (HALO) comes out ahead, leading on 2 of 2 compared factors.
Size & Scale
| DNA | HALO | |
|---|---|---|
| Market Cap | $539.34 million | $10.61 billion |
HALO leads on 1 of 1 size & scale factors.
Risk & Sentiment
| DNA | HALO | |
|---|---|---|
| Short Interest | 19.24% | 9.75% |
HALO leads on 1 of 1 risk & sentiment factors.
Dig deeper: DNA overview, DNA financials, HALO overview, HALO financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.
